Swedish personalized tissue graft company VERIGRAFT reports promising interim results from a first-in-man study in patients with deep venous insufficiency at 2023 Cell & Gene Meeting on the Mesa
One third of the patients to be included, successfully implanted with VERIGRAFT P-TEV personalized veins without need for immunosuppressants. Gothenburg, October 2, 2023: Swedish tissue graft company VERIGRAFT has announced promising interim results from the TECVI-1 first-in-man study in patients with chronic venous insufficiency (CVI) will be presented at the 2023 Cell & Gene Meeting on the Mesa. The Company has developed a pioneering technology that uses autologous components from the recipient’s blood to ensure donor veins can be implanted without the need for immunosuppressant drugs.